Clin2
NCT07206160Possibly a fitNot yet recruiting

Dapagliflozin for sepsis inflammation study

Sepsis

Part of Infections clinical trials.

This trial tests whether a diabetes medicine called dapagliflozin can help reduce inflammation in people with sepsis (a serious infection). If you are in the ICU with sepsis, this drug may improve your recovery.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
64 people
Ages
18 years to 70 years
Study type
Observational

Who can take part

  • You must be 18 or older.
  • You need to have sepsis (a severe infection) and be admitted to an intensive care unit (ICU).
  • You cannot be pregnant or breastfeeding.
  • You must not be allergic to dapagliflozin.
  • You cannot have septic shock, serious liver disease, or be on dialysis for kidney failure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06473844Recruiting
SGLT2 inhibitors for adults with sepsis

This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.

Hong Kong, Hong Kong
NCT07599644Recruiting
Sepsis Risk Study in Chinese ICU Patients

This trial studies people with and without sepsis in the ICU to understand why some get very sick from infections. It aims to find better ways to predict who will have complications and guide treatment.

Shaoguan, Guangdong
NCT07488689Not yet recruiting· Phase 3
Testing dapagliflozin for septic shock with poor blood flow

This trial tests whether a diabetes drug called dapagliflozin can help repair damaged small blood vessels in patients with septic shock. It is for people recently diagnosed with septic shock who have signs of poor blood flow to the skin.

Strasbourg
NCT05374291Enrolling by invitation· Phase 3
Dapagliflozin trial for kidney and heart outcomes in severe CKD

This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.

Canberra, Australian Capital Teritory
NCT06398977Recruiting
Dapagliflozin to protect kidney function in dialysis patients

This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.

Chengdu, Sichuan
NCT06286878Recruiting· Phase 2/Phase 3
Dapagliflozin after a heart attack: recovery study

This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.

São Paulo, São Paulo

Hear when a new Sepsis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.